FDA drug class
Classical Complement Pathway Inhibitors list
Every FDA-approved prescription drug the FDA NDC directory tags with the Classical Complement Pathway Inhibitor [EPC] class, with brand names and DEA schedules.
Source: FDA NDC Directory file dated 2026-10-22. Publisher page
The FDA NDC directory lists 1 single-ingredient drug in this class: sutimlimab.
Run it in Rivvi
Map Enjaymo and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Classical Complement Pathway Inhibitors (1)
| Drug | Brand names | Type | NDC listings | DEA schedule |
|---|---|---|---|---|
| Sutimlimab | Enjaymo | Single ingredient | 1 | Not controlled |
FDA established pharmacologic class: Classical Complement Pathway Inhibitor [EPC].
Questions
What drugs are Classical Complement Pathway Inhibitors?
The FDA NDC directory lists 1 single-ingredient drug in this class: sutimlimab.
Where does this list come from?
From the established pharmacologic class (EPC) field FDA publishes for each listing in the NDC directory. A drug is listed when most of its prescription listings carry the class.